Makarov V A, Saakian A G
Farmakol Toksikol. 1979 Sep-Oct;42(5):531-3.
The amount of free and acetylated norsulfazol in the urine of patients with gastrointestinal diseases was analysed 3 hours after peroral administration of the drug (20 mg/kg). The acetylation rate of norsulfazol in patients of 21--30 years of age was significantly lower than that in heathy subjects of the same age. In groups of 31--40, 41--50 and 51--60 years of age the acetylation rate was 47, 42 and 43%, respectively. In patients with chronic cholecystitis excretion with urine of free norsulfazol was 2-fold as increased whereas in chronic gastritis there was a 2.7-fold increase as compared to controls. The acetylation rate of norsulfazole was 1.6, 1.4 and 1.5-fold reduced in duodenal ulcer, cholecystitis and gastritis, respectively.
对患有胃肠道疾病的患者口服该药（20毫克/千克）3小时后尿液中的游离诺磺胺唑和乙酰化诺磺胺唑含量进行了分析。21至30岁患者中诺磺胺唑的乙酰化率显著低于同年龄健康受试者。在31至40岁、41至50岁和51至60岁组中，乙酰化率分别为47%、42%和43%。与对照组相比，慢性胆囊炎患者尿液中游离诺磺胺唑的排泄量增加了2倍，而慢性胃炎患者则增加了2.7倍。十二指肠溃疡、胆囊炎和胃炎患者中诺磺胺唑的乙酰化率分别降低了1.6倍、1.4倍和1.5倍。
